Diabetes Metab J.  2014 Aug;38(4):319-320. 10.4093/dmj.2014.38.4.319.

Response: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9)

• Choe E
• Kang ES

• KMID: 2174110
• DOI: http://doi.org/10.4093/dmj.2014.38.4.319

Abstract

No abstract available.

MeSH Terms

Humans

Reference

1. Choe EY, Cho Y, Choi Y, Yun Y, Wang HJ, Kwon O, Lee BW, Ahn CW, Cha BS, Lee HC, Kang ES. The effect of DPP-4 inhibitors on metabolic parameters in patients with type 2 diabetes. Diabetes Metab J. 2014; 38:211–219.

2. Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010; 53:552–561.

3. Mannucci E, Rotella CM. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Nutr Metab Cardiovasc Dis. 2008; 18:639–645.

4. Giorgino F, Leonardini A, Natalicchio A, Laviola L. Multifactorial intervention in type 2 diabetes: the promise of incretin-based therapies. J Endocrinol Invest. 2011; 34:69–77.

5. Waters SB, Topp BG, Siler SQ, Alexander CM. Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J Diabetes Sci Technol. 2009; 3:68–82.

6. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29:2632–2637.

7. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011; 71:1441–1467.

8. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012; 29:14–25.

9. Saglietti G, Placentino G, Schellino A. Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy. Clin Drug Investig. 2014; 34:513–519.

10. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011; 13:775–783.